Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
07:30am, Wednesday, 18'th Jun 2025
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to
BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO st
Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
01:50pm, Tuesday, 10'th Jun 2025
Biogen Inc. (NASDAQ:BIIB ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM ET Company Participants Robin C. Kramer - Executive VP & CFO Conference Call Participants Salve
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
07:00am, Tuesday, 03'rd Jun 2025
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
07:30am, Tuesday, 27'th May 2025
Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertise Collaboration leverages City Therapeutics' next-generation RN
Outside Days Offer Intriguing Options Opportunity
08:00am, Wednesday, 14'th May 2025
Last week, I took a closer look at outside days on a candlestick chart of the S&P 500 Index (SPX).
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
12:30pm, Monday, 12'th May 2025
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t
Paris, May 12 , 2025 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Jul
BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut
01:45pm, Thursday, 01'st May 2025
Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year.
Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript
11:38am, Thursday, 01'st May 2025
Biogen Inc. (NASDAQ:BIIB ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Tim Power - Head, Investor Relations Chris Viehbacher - President & Chief Executive Officer Priy
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Thursday, 01'st May 2025
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street e
Biogen Inc. (BIIB) Q1 Earnings Lag Estimates
09:05am, Thursday, 01'st May 2025
Biogen Inc. (BIIB) came out with quarterly earnings of $3.02 per share, missing the Zacks Consensus Estimate of $3.26 per share. This compares to earnings of $3.67 per share a year ago.
Biogen beats quarterly profit estimates on strong demand for rare disease drugs
06:48am, Thursday, 01'st May 2025
Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis drugs.
Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics
10:21am, Wednesday, 30'th Apr 2025
Get a deeper insight into the potential performance of Biogen (BIIB) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
01:11pm, Monday, 28'th Apr 2025
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
